Company intelligence / Profile preview

Oculis Innovations

Ownership: Private
Development stage: Other

Overview

Oculis has demonstrated positive results from multiple late-stage clinical trials. Its lead asset, OCS‑01, met efficacy endpoints in both Phase 2 and Stage 1 of a pivotal Phase 3 trial for diabetic macular edema. The company’s biologic candidate licaminlimab (OCS‑02) showed positive results in a large Phase 2b study for dry eye disease with biomarker-driven patient selection. The pipeline also includes a neuroprotective peptidomimetic candidate for acute optic neuritis currently advancing through early/mid-stage trials.

Therapeutic areas: OphthalmologyNeurology
Modalities: Small molecules (e.g., dexamethasone eye drops)Biologics (e.g., anti-TNFα eye drops)Peptidomimetics
Industry: Biotech

Partnerships

Novartis licensed out licaminlimab/OCS–02 to Oculis; supported by leading international healthcare investors.

Beyond the preview

Go deeper on Oculis Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oculis Innovations.

Explore the full profile